Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Canadian HIV Quit Smoking Trial: Tackling the Co-morbidities of Depression and Cardiovascular Disease in HIV+ Smokers
Brief Summary: The objectives of this trial are:

Primary objectives:

1. To determine among HIV+ individuals whether varenicline or NRT is more effective at helping individuals remain abstinent from smoking tobacco.
2. To determine among HIV+ individuals whether varenicline or NRT has the lowest side-effect profile.
3. To determine if the HIV tailored Quit Smoking Counselling Intervention, plus smoking cessation drug therapy, improves smoking cessation rates compared to smoking cessation drug therapy alone with usual care.

Secondary objective:

1. To determine whether the use of varenicline/NRT is safe in HIV+ patients who exhibit depressive symptoms.

Hypothesis:

That varenicline will result in higher quit smoking rates and that NRT will result in a lower side effect profile. Further, the HIV tailored quit smoking intervention will result in higher rates of smoking cessation over and above the pharmacological treatment alone. And finally, varenicline will be safe to use for HIV + individuals who exhibit depressive symptoms.


Options:
A: Arm Label: Tailored Intervention Group; Type: EXPERIMENTAL; Interventions: Drug: Nicotine replacement therapy - transdermal nicotine patch, Behavioral: Tailored behavioral intervention, Drug: Nicotine replacement therapy - nicotine gum, Drug: Nicotine replacement therapy - nicotine lozenge, Drug: Bupropion Sustained Release, Drug: Varenicline, Drug: Combination pharmacotherapy - transdermal nicotine patch + nicotine gum, Drug: Combination pharmacotherapy - transdermal nicotine patch + nicotine lozenge, Drug: Combination pharmacotherapy - transdermal nicotine patch + bupropion, Behavioral: Alcohol use risk reduction, Behavioral: Behavioral activation for the treatment of depression, Behavioral: Behavioral management of post-cessation weight gain | Arm Label: Enhanced Standard of Care Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine replacement therapy - transdermal nicotine patch, Behavioral: Tobacco quit line referral, Drug: Nicotine replacement therapy - nicotine gum, Drug: Nicotine replacement therapy - nicotine lozenge, Drug: Bupropion Sustained Release, Drug: Varenicline, Drug: Combination pharmacotherapy - transdermal nicotine patch + nicotine gum, Drug: Combination pharmacotherapy - transdermal nicotine patch + nicotine lozenge, Drug: Combination pharmacotherapy - transdermal nicotine patch + bupropion | Intervention Type: DRUG; Name: Nicotine replacement therapy - transdermal nicotine patch; Assigned to Arm(s): Enhanced Standard of Care Group, Tailored Intervention Group | Intervention Type: BEHAVIORAL; Name: Tailored behavioral intervention; Assigned to Arm(s): Tailored Intervention Group | Intervention Type: BEHAVIORAL; Name: Tobacco quit line referral; Assigned to Arm(s): Enhanced Standard of Care Group | Intervention Type: DRUG; Name: Nicotine replacement therapy - nicotine gum; Assigned to Arm(s): Enhanced Standard of Care Group, Tailored Intervention Group | Intervention Type: DRUG; Name: Nicotine replacement therapy - nicotine lozenge; Assigned to Arm(s): Enhanced Standard of Care Group, Tailored Intervention Group | Intervention Type: DRUG; Name: Bupropion Sustained Release; Assigned to Arm(s): Enhanced Standard of Care Group, Tailored Intervention Group | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Enhanced Standard of Care Group, Tailored Intervention Group | Intervention Type: DRUG; Name: Combination pharmacotherapy - transdermal nicotine patch + nicotine gum; Assigned to Arm(s): Enhanced Standard of Care Group, Tailored Intervention Group | Intervention Type: DRUG; Name: Combination pharmacotherapy - transdermal nicotine patch + nicotine lozenge; Assigned to Arm(s): Enhanced Standard of Care Group, Tailored Intervention Group | Intervention Type: DRUG; Name: Combination pharmacotherapy - transdermal nicotine patch + bupropion; Assigned to Arm(s): Enhanced Standard of Care Group, Tailored Intervention Group | Intervention Type: BEHAVIORAL; Name: Alcohol use risk reduction; Assigned to Arm(s): Tailored Intervention Group | Intervention Type: BEHAVIORAL; Name: Behavioral activation for the treatment of depression; Assigned to Arm(s): Tailored Intervention Group | Intervention Type: BEHAVIORAL; Name: Behavioral management of post-cessation weight gain; Assigned to Arm(s): Tailored Intervention Group
B: Intervention Type: DRUG; Name: CP-526,555 (varenicline); Assigned to Arm(s): N/A
C: Arm Label: NRT arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine Replacement Therapy (NRT) | Arm Label: NRT and HIV Tailored Quit Smoking Counseling; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine Replacement Therapy (NRT), Behavioral: HIV Tailored Quit Smoking Counseling | Arm Label: Varenicline (VR) Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Varenicline (VR) and HIV Tailored Quit Smoking Counseling; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline, Behavioral: HIV Tailored Quit Smoking Counseling | Intervention Type: DRUG; Name: Nicotine Replacement Therapy (NRT); Assigned to Arm(s): NRT and HIV Tailored Quit Smoking Counseling, NRT arm | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline (VR) Arm, Varenicline (VR) and HIV Tailored Quit Smoking Counseling | Intervention Type: BEHAVIORAL; Name: HIV Tailored Quit Smoking Counseling; Assigned to Arm(s): NRT and HIV Tailored Quit Smoking Counseling, Varenicline (VR) and HIV Tailored Quit Smoking Counseling
D: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Transdermal Nicotine Patch; Type: EXPERIMENTAL; Interventions: Drug: Transdermal Nicotine Patch | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Transdermal Nicotine Patch; Assigned to Arm(s): Transdermal Nicotine Patch

Answer: C